Abstract:Abstract There are long-standing concerns that the use of biologic therapies to treat patients with psoriasis could confer an increased risk of developing cancer due to their immunomodulatory effects. We aimed to assess the risk of any incident cancer (excluding keratinocyte carcinoma, KC), hereafter termed ‘incident cancer’, in patients with moderate-to-severe psoriasis treated with biologic therapy compared with nonbiologic systemic therapy. We used data from BADBIR, a multicentre register evaluating the long-term safety and effectiveness of systemic therapy for patients with moderate-to-severe psoriasis, between September 2007 and November 2023, with linkage to data from NHS Digital to ascertain incident cancers not captured in BADBIR. Eligible for inclusion were patients with chronic plaque psoriasis, who were biologic naive at registration to BADBIR, who had no personal history of cancer (excluding KC) and who had completed at least one follow-up visit. To balance between the compared groups in their baseline characteristics, we calculated probability-weighted regression adjustment estimators with a propensity score model including age, sex, body mass index, smoking, alcohol consumption, previous exposure to nonbiologic systemic therapy and number of comorbidities. Therefore, these weights were used in a flexible parametric survival model to estimate hazard ratios for developing incident cancers, using imputed data. There were 11 185 patients (66%) registered to the biologic cohort and 5673 patients (34%) to the nonbiologic systemic cohort. The biologic cohort was older (median age 44 years, interquartile range 34–54 vs. 42 years, interquartile range 32–53), with more men (59% vs. 57%) and comorbidities (68% vs. 61%) compared with the nonbiologic systemic cohort. Patients in the biologic cohort contributed 73 643 person-years of follow-up and patients in the nonbiologic systemic cohort contributed 23 694 person-years. During follow-up, 467 patients (4%) in the biologic cohort and 169 patients (3%) in the nonbiologic systemic cohort developed incident cancer. There was no significant difference in the risk of developing incident cancer between the biologic cohort and the nonbiologic systemic cohort (adjusted hazard ratio 0.88, 95% confidence interval 0.69–1.11). The results from these real-world data are reassuring for patients with psoriasis and clinicians, as it appears that treatment with biologic therapy does not confer an increased risk of developing overall cancer (excluding KC), in the short-to-medium term, compared with nonbiologic systemic therapy. However, given the heterogeneity of all cancers combined, risks of developing cancers from common subgroups or site-specific cancers (breast, prostate, lung, colorectal and melanoma) in biologic-treated patients need to be investigated. This study is funded by the Psoriasis Association.

Increased risk of malignancy in HLA-B27-positive patients with ankylosing spondylitis requiring biologics for sustained inflammation: A long-term, single-center retrospective study

Concurrent Ankylosing Spondylitis and Myelodysplastic Syndrome: A Case Report

Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study

[Clinical Analysis of 31 Ankylosing Spondylitis Patients with Malignancies].

HLA-B*27 and Ankylosing Spondylitis: 50 Years of Insights and Discoveries

Malignancy Development Risk in Psoriatic Arthritis Patients Undergoing Treatment: A Systematic Review and Meta-Analysis

Association of ankylosing spondylitis with the risk of cancer: a meta- analysis of cohort studies

P072 Risk of incident cancer, excluding keratinocyte carcinoma, in patients with psoriasis treated with biologic therapy: a prospective cohort study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR), on behalf of the BADBIR Study Group

Large-scale genome-wide association studies reveal the genetic causal etiology between ankylosing spondylitis and risk of leukemia and lymphocytic malignancies

Increased Risk for Pulmonary Embolism among Patients with Ankylosing Spondylitis—Results from a Large Database Analysis

Incidence of Malignancies and the Association with Biological Disease-Modifying Antirheumatic Drugs in Japanese Patients with Rheumatoid Arthritis: A Time-Dependent Analysis from the IORRA Patient Registry

P456 Risk of Malignant Tumors in Patients with Autoimmune Diseases on Ustekinumab Therapy: a Systematic Review and Meta-Analysis

Factors Associated with the Risk of Major Adverse Cardiovascular Events in Patients with Ankylosing Spondylitis: A Nationwide, Population-Based Case—Control Study

A Meta-Analysis of Biologic Therapies on Risk of New or Recurrent Cancer in Patients with Rheumatoid Arthritis and a Prior Malignancy.

Real-World Adherence and Drug Survival of Biologics among Patients with Ankylosing Spondylitis

Impact of inflammation and anti-inflammatory therapies on the incidence of major cardiovascular events in patients with ankylosing spondylitis: A population-based study

Trends in the use of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and recently diagnosed colorectal, lung, or prostate cancer

Risk of motor vehicle accidents with profound injuries in patients with ankylosing spondylitis: a nationwide, population-based cohort study

Is low-dose tumor necrosis factor inhibitor effective and safe in patients with ankylosing spondylitis flare-up after renal transplantation? A case report and literature review

[DMARD (disease-modifying antirheumatic drug) treatment in patients with former or current cancer]

Advance of Research on HLA-B27 and the Immunological Mechanism of Ankylosing Spondylitis